source
- Scholar Rock pulls Indiana fill-finish plant from SMA therapy filing after FDA flags violationsScholar Rock has removed Novo Nordisk's former Catalent fill‑finish facility in Bloomington, Indiana, from its regulatory filing for a spinal muscular atrophy therapy after the FDA classified the p…
- Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancerAura Biosciences is refocusing under its recently installed CEO, laying off 20% of its employees and overhauling its C-suite as it narrows its focus on ocular oncology.Fierce Biotech · 11h ago↗ source